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Abstract 
 
The present investigation was carried out to evaluate the biochemical effect of Withania somnifera Linn. Solanaceae, 
commonly known as ashwagandha on adjuvant induced arthritic rats. Results were compared to Indomethacin, a non 
steroidal anti-inflammatory drug. Arthritis was induced by an intra dermal injection of Complete Freund’s Adjuvant 
(0.1 mL) into the right hind paw of Wistar albino rats. Withania somnifera root powder (1000 mg/kg/day) and 
Indomethacin (3 mg/kg/day) were orally administered for 8 days (from 11th to 18th day) after adjuvant injection. After 
the experimental period, all the animals were sacrificed and serum, liver and spleen samples were collected for further 
biochemical analysis. A significant increase in the activities of gluconeogenic enzymes, tissue marker enzymes, blood 
glucose level, WBC, platelet count, erythrocyte sedimentation rate, and acute phase proteins (hyaluronic acid, 
fibrinogen and ceruloplasmin) was observed in adjuvant-induced arthritic rats, whereas the activities of glycolytic 
enzymes, body weight, levels of hemoglobin, RBC count, and packed cell volume were found to be decreased. These 
biochemical alterations observed in arthritic animals were ameliorated significantly after the administration of Withania 
somnifera root powder (1000 mg/kg/b.wt) and Indomethacin (3 mg/kg/b.wt). Our results suggest that Withania 
somnifera root powder is capable of rectifying the above biochemical changes in adjuvant arthritis and it may prove to 
be useful in treating rheumatoid arthritis. 
 
 
Abstrak 
 
Evaluasi Biokimiawi Bubuk Akar Withania somnifera pada Tikus yang Diinduksi Adjuvant-Arthritis. Penelitian 
saat ini dilakukan untuk mengevaluasi efek biokimiawi dari Withania somnifera Linn. Solanaceae, yang juga dikenal 
sebagai ashwagandha, pada tikus yang diinduksi adjuvant-arthritic. Hasil penelitian kemudian dikomparasi terhadap 
Indomethacin, yang merupakan obat anti peradangan non-steroid. Arthritis diinduksi dengan menggunakan injeksi 
Complete Freund’s Adjuvant (0,1 mL) secara intra-dermal ke telapak kaki belakang tikus Wistar albino. Akar Withania 
somnifera bubuk (1000 mg/kg/hari) dan Indomethacin (3 mg/kg/hari) diberikan secara oral selama 8 hari (dari hari ke 
11-18) pasca dilakukannya injeksi adjuvant. Setelah masa experimen, seluruh hewan percobaan dikorbankan, kemudian 
sampel limpa, hati, dan serum dikumpulkan untuk analisis biokimiawi lebih jauh. Pada tikus-tikus yang diinduksi 
adjuvant-arthritic, terdapat peningkatan signifikan dalam aktifitas enzim glukoneogenesis, enzim petanda jaringan, 
level glukosa darah, jumlah sel darah putih (WBC), jumlah keping darah, tingkat sedimentasi eritrosit, dan protein fase 
akut (asam hyaluronic, fibrinogen dan ceruloplasmin). Sementara itu, terjadi penurunan aktifitas enzim glikolisis, berat 
tubuh, level hemoglobin, jumlah sel darah merah (RBC), dan volume sel yang dimampatkan (PCV). Kondisi perubahan 
biokimiawi yang terjadi pada hewan penderita arthritis ini membaik secara signifikan setelah pemberian bubuk akar 
Withania somnifera (1000 mg/kg/b.wt) dan Indomethacin (3 mg/kg/b.wt). Hasil penelitian mengindikasikan bahwa 
bubuk akar Withania somnifera dapat menyembuhkan perubahan biokimiawi pada adjuvant-arthritis yang disebutkan 
di atas. Hasil ini dapat bermanfaat dalam perawatan kondisi rheumatoid-arthritis. 
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Introduction  
 
Withania somnifera Linn.Dunal, a solanaceae, commonly 
known as Ashwagandha, is an Indian ayurvedic medicinal 
plant used in several indigenous drug preparations 
prescribed for common diseases of respiratory and 
reproductive tracts.1 It is an evergreen tomentose shrub, 
grown wild and also cultivated to improve overall 
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physical and mental health in many parts of India. 
Currently Withania somnifera root extract is used as a 
dietary supplement in the United States, and has received 
worldwide attention for its pharmacological activities. 
Withania somnifera has been shown to have promising 
antibacterial, anti tumour, and immune modulating 
properties.2 Withania somnifera has been used as a 
remedy since ancient times for all age groups of both 
sexes and even during pregnancy without toxic effects.3 
Withania somnifera root has been considered to have 
therapeutic purposes.4  
 
The root of Withania somnifera contain several alkaloids, 
with anolides, a few flavanoids and reducing sugars and 
was shown to have free radical scavenging activity. It 
has been reported that Withania somnifera contain active 
compounds like with aferin A, sitoindosides VII–X, 5-
dehydroxywithanolide-R, with asomniferin-A,1-oxo-
5ß,6ß-epoxy-witha-2-ene-27-ethoxy-olide, 2,3-dihydro 
withaferin A, 24,25-dihydro-27-desoxywithaferin A, 27-
O-ß-D-glucopyranosylphysagulin D, physagulin D, with-
anoside I–VII, 27-O-ß-D-glucopyranosylviscosalactone 
B, 4,16-dihydroxy-5ß, 6ß-epoxyphysagulin D, visco 
salactone B, and diacetylwithaferin A and they are 
suggested to have anti-cancer, anti-oxidative and anti-
mutagenic properties.5,6 These above reports indicate that 
Withania somnifera is a rich source of bioactive 
compounds. Our preliminary studies indicated that 
Withania somnifera root powder has promising anti-
arthritic activity by way of decreasing paw diameter and 
lysosomal enzyme activities.7 
 
Rheumatoid arthritis is a chronic auto immune disorder 
characterized by non-specific, usually symmetric 
inflammation of the peripheral joints.8 The long-term 
prognosis of this disease is characterized by significant 
morbidity, loss of functional capacity, and increased 
mortality. This disease affects about 1% of the general 
population worldwide.9 Non-steroidal anti-inflammatory 
drugs such as Indomethacin and naproxen are frequently 
used as first-line therapies for rheumatoid arthritis; 
however, these agents may have serious side effects 
such as gastrointestinal toxicity, renal toxicity, or gastro-
intestinal bleeding.10 Therefore we focused our research 
to find out a drug with long acting anti-inflammatory 
activity and minimum side effects from plant resources. 
Hence this study was carried out to reveal the effect of 
Withania somnifera root powder on carbohydrate meta-
bolism, hematological constituents and tissue enzymes 
in adjuvant induced arthritis, an experimental model for 
rheumatoid arthritis in rats. The standard non-steroidal 
anti-inflammatory drug, Indomethacin, was used as 
reference drug for purposes of comparison. 
 
Methods 
 
Animals. The study was performed with Wistar strain 
albino rats, 120-150grams, of either sex. The rats were 
brought from Tamilnadu Veterinary College, Chennai 
India. Rats were acclimated for a week in a light and 
temperature–controlled room with 12 hour dark-light 
cycle. The rats were fed with commercial pelleted feed 
from Hindustan Lever Ltd. (Mumbai, India) and water 
was freely available. 
 
Pharmacological agents. The commercially available 
powdered root of Withania somnifera was obtained 
from Indian Medical Practitioners Co-operative Stores 
and Society (IMCOPS), Adyar, Chennai, India and its 
aqueous suspension in 2% gum acacia was used at a 
dose of 1000 mg/kg/day. Indomethacin (Tamil Nadu 
Dadha Pharmaceuticals, Chennai, India) was dissolved 
in 2% gum acacia solution and then was administrated 
at a dosage of 3 mg/kg/day.7 All other reagents like 
glucose, glucose-6-phophate, fructose 1,6-bisphosphate, 
dinitrophenyl hydrazine, ATP, disodium phenyl 
phosphate and sodium pyurvate were used and 
purchased locally. 
 
Experimental design. The rats were divided into six 
groups, each group comprising of six animals. Group I 
served as the control group. In Group II arthritic control, 
arthritis was induced by intradermal injection of 
Complete Freund’s Adjuvant (0.1 mL) into the right 
hind paw.7 The adjuvant (Tuberculosis Research Center, 
Chennai, India) contained heat-killed Mycobacterium 
tuberculosis (10 mg) in paraffin oil (1 mL). Group III 
and IV drug controls were treated with Withania 
somnifera (1000 mg/kg b.wt) and Indomethacin (3 
mg/kg b.wt), respectively, for 8 days. Groups V and VI 
comprised of arthritic rats that were treated with 
Withania somnifera and Indomethacin, respectively, 
from days 11 to 18 after the administration of Complete 
Freund’s Adjuvant. 
 
Body weight changes of the experimental groups at 
different periods up to 19 days, following the injection 
of Complete Freund’s Adjuvant were recorded. On the 
19th day, at the end of the experimental period, the 
animals were sacrificed by cervical decapitation, and the 
blood was collected. The liver and spleen were 
immediately dissected out and homogenized in ice-cold 
0.01 M, Tris HCL buffer, pH 7.4 to give a 10% 
homogenate. The serum, liver and spleen tissue 
homogenate were used for assaying the following 
hematological and biochemical parameters. 
 
The activities of glucose metabolizing enzymes, 
hexokinase,11 aldolase,12 phosphoglucoisomerase,13 
fructose-1-6-diphosphatase,14 and glucose-6-phosphatase12 
were determined in the liver and spleen. Blood glucose 
was estimated by the method of Sasaki, et al. (1972).15 
and the protein content was measured by the method of 
Lowry, et al. in 1951.16 Tissue enzymes namely 
aspartate transaminase,17 alanine transaminase,17 alkaline 
phosphatase,18 and lactate dehydrogenase12 were 
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estimated in plasma, liver, and spleen respectively to 
investigate the anti-arthritic affect of Withania 
somnifera. Hematological constituents namely 
hemoglobin,19 RBC, WBC,20 platelet count,21 
erythrocyte sedimentation rate,22 packed cell volume,23 
serum hyaluronic acid,24 fibrinogen,25 and ceruloplasmin26 
were estimated. 
 
Statistical analysis. The results were expressed as 
mean±SD and statistical analysis was performed using 
ANOVA, to determine the significant differences 
between the groups, followed by Student’s Newman-
Keul’s test, p<0.05 implied significance. 
 
Results and Discussion 
 
Figure 1 shows the changes in body weight of the 
control group and experimental group rats. The growth 
of arthritic rats (Group II) was found to be retarded, 
compared to normal rats. The body weight of Withania 
somnifera treated arthritic rats (Group V) was found to 
increase when compared to that of control rats. 
 
Table 1 presents the glycolytic and gluconeogenic 
enzyme activities in the liver and spleen of experimental 
animals. The activities of glycolytic enzymes were 
significantly decreased, whereas gluconeogenic enzymes 
and blood glucose level were found to be increased in 
Group II arthritic rats, when compared to Group I 
control rats. The administration of Withania somnifera 
root powder and Indomethacin to arthritic rats reversed 
the above changes to normal level considerably, the 
effect being equal to that of Indomethacin. 
 
Table 2 depicts the levels of hematological constituents, 
serum hyaluronate, and acute phase proteins of the 
control group and experimental group rats. The arthritic 
rats (Group II) showed a significant decrease in the 
level of hemoglobin, RBC count, packed cell volume, 
and an increase in WBC, platelet count, erthyrocyte 
sedimentation rate (ESR), hyaluronic acid, fibrinogen, 
and ceruloplasmin when compared to normal animals. 
These alterations were significantly reversed to near 
normal levels in Withania somnifera root powder 
treated arthritic rats (Group V), the effect being better 
than that of Indomethacin. 
 
Table 3 shows the effect of Withania somnifera root 
powder on the changes of alanine transaminase, aspartate 
transaminase, alkaline phosphatase and lactate dehydro-
genase in the control and experimental groups. A marked 
increase in alanine transaminase, aspartate transaminase, 
alkaline phosphatase, and lactate dehydrogenase was 
observed in Group II arthritic rats. Withania somnifera 
root powder treated arthritic rats (Group V) showed a 
significant decrease in the level of alanine transaminase, 
aspartate transaminase, alkaline phosphatase, and lactate 
dehydrogenase than Indomethacin, when compared to 
arthritic control rats (Group II). 
 
Rheumatoid arthritis is a chronic relapsing immune 
inflammatory multisystem disease with predominant 
synovial proliferation and destruction of the articular 
cartilage.27 Etiology of rheumatoid arthritis still remains 
obscure despite extensive research. The pathogenesis of 
rheumatoid arthritis is multifactorial and recent research 
has implicated oxygen free radicals as mediators of tissue 
damage.28 Changes in the body weight are a useful index 
to assess the course of the disease and the response to 
therapy of anti-inflammatory drugs in quest.29 
 
The loss of body weight observed in arthritic rats may 
be due to the reduced absorption of glucose and leucine 
in the intestine of the rat.30 The increase in body weight 
during Withania somnifera root powder administration 
reveals the restoration of absorption capacity of the 
intestine in the arthritic rats. 
 
 
Figure 1. Effect of Withania somnifera and Indomethacin on Body Weight Changes 
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Table 1.  Effect of Withania somnifera Root Powder and Indomethacin on Glycolytic and Gluconeogenic Enzymes Activity in 
Control and Experimental Arthritic Rats 
 
Enzymes Group I Group II Group III Group IV Group V Group VI 
Liver       
Hexokinase  20.44±1.76 15.63±1.35a* 20.51±1.77 20.64±1.78 19.20±1.66 b* 18.51±1.60 b* 
Aldolase  18.20±1.57 13.54±1.17a* 18.36±1.59 18.21±1.57 17.26±1.49 b* 16.54±1.43 b* 
Phosphoglucoisomerase  19.30±1.67 14.63±1.26a* 19.41±1.68 19.28±1.67 18.54±1.60 b* 16.26±1.49 c* 
Glucose -6- phosphatase  17.54±1.52 21.12±1.82a* 17.26±1.49 17.17±1.48 16.39±1.41 b* 17.72±1.53 b* 
Fructose 1,6- diphosphatase 18.63±1.61 21.72±1.87a* 18.71±1.61 18.81±1.63 19.16±1.65 b* 19.21±1.66 b* 
Spleen       
Hexokinase  12.54±1.08 9.20±0.79 a* 12.63±1.09 12.71±1.09 11.79±1.01 b* 10.83±2.01 a*b* 
Aldolase  13.54±1.17 10.26±0.88a* 13.24±1.14 13.13±1.13 12.82±1.11 b* 12.56±1.08 b* 
Phosphoglucoisomerase  16.24±1.40 12.54±1.08a* 16.33±1.41 16.28±1.40 15.78±1.36 b* 15.26±1.31 b* 
Glucose -6- phosphatase  16.08±1.39  21.26±1.83a* 16.27±1.41 16.11±1.40 17.43±1.50 b* 18.36±7.59 b* 
Fructose 1,6-diphosphatase 21.54±1.86 26.82±2.32a* 21.26±1.83 21.18±1.83 22.61±1.96 b* 23.12±2.00 b* 
Blood glucose 101.27±9.44 129.48±5.88a* 100.29 ±9.55 100.75±9.75 110.40 ±5.30 b* 108.34±3.42 b* 
Values are mean±SD for six animals in each group 
One unit of enzyme activity is expressed as: Hexokinase–nanomoles of glucose–6-phosphate; Aldolase–nanomoles of glyceraldehyde, 
Phosphoglucoisomerase-nanomoles of fructose –formed/minute mg protein at 37°C. Glucose-6-phosphatase and fructose-1,6-diphosphatase –
nanomoles of inorganic phosphorus released/minute/mg protein at 37°C. Comparisons are made between: aGroup I and Group II, III, IV, V, VI; 
bGroup II and Group V, VI; cGroup V and Group VI. The symbol represent statistical significance at-p<0.05 
 
 
Table 2. Effect of Withania somnifera Root Powder and Indomethacin on Haematological Parameters, Serum Hyaluronate 
and Acute Phase Proteins in Control and Experimental Arthritic Rats 
 
Parameters Group I Group II Group III Group IV Group V Group VI 
Hb (g/dL) 14.40±0.79 10.36±1.21 a* 14.60±1.13 14.30±1.38 13.51±1.16 b* 12.33±1.56 a* 
RBC 3.71±0.19 3.32 ±0.22 a* 3.77±0.26 3.74±0.26 3.63±0.26 3.54 ±0.25  
WBC 7.43 ±0.55 17.03 ±1.21 a* 7.30±0.58 7.52±0.54 9.56±0.79 a* b * 11.32± 0.78 a*b*c* 
Platelet count 2.55 ±0.14 4.44 ±0.36 a* 2.57±0.17 2.50±0.15 2.62±0.18 b* 2.86±0.20 a*b* 
Packed cell volume % 33.73±2.54 26.61 ±2.14 a* 34.0 ±2.34 34.26±3.00 30.31±2.17 b* 29.38±2.84 a* 
ESR (mm)       
30 min 3.02±0.22 10.35 ±0.95 a* 2.59 ±0.17 2.77±0.16 6.23±0.40 a* b* 8.92±0.74 a*b*c* 
60 min 5.03±0.34 14.45 ±0.96 a* 4.77±0.29 5.49±0.45 8.4 0±0.61 a*b* 11.60 ±0.85 a*b*c*  
Hyaluronate (µg/mL) 90.09±5.68 183.00±15.8 a* 85.34±9.13 95.26±9.37  102.20±7.20 b* 126.50±11.6 a*b*c* 
Fibrinogen (mg/dL) 47.95±4.46 201.84±11.7 a* 53.43±6.38 52.21±5.68 88.93±9.31 a*b* 127.92±11.82 a*b*c* 
Ceruloplasmin (mg/dL) 16.68±2.11 31.27±4.1a* 17.02±2.49 16.96±1.93 19.79±3.27 b* 23.31±2.56 a*b*c* 
Values are mean±SD for six animals in each group 
Comparisons are made between: aGroup I and Group II, III, IV, V, VI; bGroup II and Group V, VI; cGroup V and Group VI. The symbol represent 
statistical significance at-*p<0.05 
 
 
During arthritic condition, glycolysis and citric acid 
cycle enzyme activities were found to be altered.31,32 
Our present study agreed those previous reports because 
the glycolytic enzyme activities were significantly 
decreased, whereas the gluconeogenic enzymes were 
found to be increased in the liver and spleen of arthritic 
rats. Reduced glucose transport or accumulated gluco-
neogenic substrates at tissue sites may inhibit glycolytic 
enzymes in the arthritic rats (Group II). Enlargement of 
the adrenal gland during adjuvant induced arthritis 
coincides with the detection of increased amount of plasma 
corticosterone.33 The increased plasma corticosterone 
level in arthritic condition stimulates gluconeogenic 
activity in the tissues, with a resultant increase in the 
activities of these gluconeogenic enzymes. 
 
Inflammatory changes in the joints may alter the normal 
equilibrium between the entry and utilization of 
glucose.34 The decreased glycolytic and increased 
gluconeogenic enzymes or the impaired transport of 
glucose into the joints might cause an increase in the 
blood glucose level during arthritis. The administration 
of Withania somnifera root powder and Indomethacin to 
arthritic animals brought the above changes to near 
normal levels. The effect of Withania somnifera in 
arthritic animals is almost equal to that of Indomethacin. 
 
The decrease in hemoglobin content seen in arthritic rats 
may contribute to the anemia which may be due to 
reduced erythrocyte deformability and an increase in 
spleen weight.35,36 The reduced deformability leads to a 
shortened life span of erythrocytes,37 which results in the 
depression of RBC levels. In arthritic rats, WBC, and 
platelet count were increased which are responsible for 
the destruction of invading pathogenic microorganisms.38 
Clinical observations and measurement of erythrocyte 
sedimentation rate serves as a useful marker for 
rheumatoid arthritis.39 The level of serum hyaluronate
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Table 3.  Effect of Withania somnifera Root Powder and Indomethacin on the Activities of Tissue and Serum Enzymes in 
Control and Experimental Arthritic Rats 
 
Parameters 
Units/mg protein 
 
Group I 
Control 
Group II Group III Group IV Group V Group VI 
Arthritis Withania sommnifera 
root powder 
Indomethacin Arthritis + 
Withania sommnifera 
root powder 
Arthritis+ 
Indomethacin 
 
Plasma 
      
Alanine transaminase 0.58±0.07 1.12±0.11a 0.61±0.07 0.63±0.07 0.70±0.07a*b* 0.84±0.09 a*b*c* 
Aspartate transaminase 0.52±0.06 0.98±0.12a* 0.48±0.06 0.51±0.07 0.61±0.05a*b* 0.66±0.07a*b*c* 
Alkaline phosphatase 2.70±0.20 5.96±0.4 8a* 2.55±0.27 2.78±0.28 2.75±0.34 a* 2.72±0.25 b* 
Lactate dehydrogenase 5.44±0.47 10.87±1.3 a* 5.68±0.48 5.47±0.53 6.88±0.68 a*b* 8.25±0.76a*b*c* 
 
Liver 
      
Alanine transaminase 0.13±0.02 0.36±0.05 a* 0.15±0.03 0.13±0.01 0.19±0.04a*b* 0.22±0.03 a*b* 
Aspartate transaminase 0.15±0.04 0.33±0.05 a* 0.15±0.02 0.17±0.03 0.19±0.03a*b* 0.23±0.03 a*b* 
Alkaline phosphatase 1.29±0.13 3.51±0.23 a* 1.24±0.17 1.28±0.14 1.46±0.16 b* 1.79±0.17 a*b*c* 
Lactate dehydrogenase 10.81±1.51 19.2±1.9 a* 10.64±1.52 9.93±1.37 10.83±1.60 b* 14.48±1.72a*b*c* 
 
Spleen 
      
Alanine transaminase 0.16±0.01 0.41±0.04 a* 0.18±0.01 0.16±0.03 0.28±0.05 a*b* 0.31±0.04 a*b* 
Aspartate transaminase 0.23±0.02 0.67±0.06 a* 0.21±0.02 0.25±0.02 0.41±0.07 a*b* 0.51±0.04 a*b*c* 
Alkaline phosphatase 0.55±0.04 0.90±0.10 a* 0.53±0.05 0.52±0.08 0.62±0.05 b* 0.71±0.06 a*b*c* 
Lactate dehydrogenase 4.85±0.48 9.56±0.85 a* 4.54±1.08 4.96±0.40 6.06±0.29 a*b* 7.85±0.65 a*b*c* 
 
Values are mean ± SD for six animals in each group  
Comparisons were made as in Table 1. Enzymes unit: Aminotransferases -µ moles x 10-2 of pyruvate; ALP-µ moles x of phenol; LDH-µ moles x 10-1 
of pyruvate liberated /min/mg protein.The symbols represent statistical significance at: *p<0.05 
 
 
is another reliable index of arthritic severity.40,41 
Normally serum hyaluronate is low but in active and 
destructive rheumatoid arthritis, the levels increase 
significantly. In the present study, serum hyaluronate 
increased in adjuvant arthritis may be due to its release 
from tissues and inflamed joints in the arthritic animals. 
The increase in plasma fibrinogen might be due to the 
result of liver stimulation by the products of tissue 
disintegration.42 Plasma fibrinogen is deposited excess 
as fibrin in synovial fluid in rheumatoid arthritis. It 
plays a vital role in the inflammatory joint diseases and 
its level serves as a useful marker to assess the 
progression of arthritis.43 
 
Ceruloplasmin acts as an extracellular scavenger of 
superoxide radicals44 and is likely to participate in the 
inhibition of lipid peroxidation formation, during 
inflammation, through oxidation of ferrous molecules 
required for free radicals generation.45 The increased 
secretion of hormones and mediators like interleukin-1, 
epinephrine, and glucocorticoids released during 
arthritis might be responsible for the elevation of serum 
ceruloplasmin in Group II arthritic rats. Ceruloplasmin 
is synthesized in the liver in response to tissue injury 
and is released into the blood circulation.46 The elevated 
serum ceruloplasmin level in arthritic animals appears 
to correlate with the increased antioxidant activity.47,48 
Administration of Withania Somnifera root powder 
significantly decreased the level of serum hyaluronate 
and acute phase proteins and normalized the 
hematological changes in arthritic rats, the effect being 
better than that of Indomethacin. 
Tissue damage was assessed by measuring the activities 
of enzyme in the serum and in the respective organs. 
The increase in aminotransferases is due to the release 
from the cells of the liver, since liver impairment is also 
a feature of adjuvant arthritis.49 Alkaline phosphatase 
has been reported to be present mainly in the blood 
vessels, pia arachnoid and choroid plexus. Alkaline 
phosphatase activity has been reported to increase 
during the morphological and functional development of 
the tissues. Lactate dehydrogenase was significantly 
increased in arthritic rats. Reduction in the lactate 
dehydrogenase level after Withania somnifera root 
powder treatment may be due to the inhibition of the 
release of osteosarcoma collagenase and neutrophil, 
which indicate the membrane stabilizing effect of 
Withania somnifera. Alanine transaminase, aspartate 
transaminase, alkaline phosphatase and lactate 
dehydrogenase were significantly reduced in arthritic 
rats after the administration of Withania somnifera root 
powder than Indomethacin. This reducing effect of 
Withania somnifera may be related to their anti-
inflammatory activity. The beneficial effect of Withania 
somnifera observed in this study might be due to the 
presence of various active principles in its roots. It is 
known that Withania somnifera root powder is popularly 
used as a home remedy for several diseases such as 
arthritis, geriatric problems, fever, tuberculosis, asthma, 
and it is an official drug mentioned in the Indian 
Pharmacopoeia. Based on the significance observed 
between Withania somnifera (Group-V) and 
Indomethacin treated (Group-VI) arthritic animals in our 
study, it may be suggested that Withania somnifera 
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exerts a more promising anti-inflammatory effect than 
Indomethacin. Withania somnifera can be used as a 
potential anti-arthritic drug as an alternative to 
Indomethacin in the treatment of rheumatoid arthritis. 
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